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ABSTRACT
Objective: The adoption and diffusion of new medical treat-
ments depend increasingly on evidence of costs and cost-
effectiveness. This evidence is increasingly being generated
from economic data collected in randomized clinical trials.
The objective of this article is to evaluate the statistical meth-
ods used for analysis of cost data in economic evaluations
conducted alongside randomized controlled trials.
Methods: Systematic review of economic evaluations based
on patient-level cost or resource-use data collected in rand-
omized trials was published in 2003. One hundred ﬁfteen
articles were identiﬁed from the MEDLINE database. The
use of statistical methods for 1) joint comparison of costs and
effects and assessment of stochastic uncertainty, 2) incremen-
tal cost estimation, and 3) handling of incomplete or cen-
sored cost data was evaluated.
Results: Only 42 (37%) of the 115 economic evaluations
presented a cost-effectiveness ratio or estimated net beneﬁts
and 24 (57%) of these reported the uncertainty of this sta-
tistic. A comparison of costs alone was more common with
92 (80%) of the 115 studies statistically comparing costs
between treatment groups. Of these, about two-thirds (62;
68%) used at least one statistical test appropriate for draw-
ing inferences for arithmetic means. Incomplete cost data
were reported in 67 (58%) studies with only two using a
published statistical approach for handling censored cost
data.
Conclusion: The quality of statistical methods used in eco-
nomic evaluations conducted alongside randomized control-
led  trials  was  poor  in  the  majority  of  studies  published
in 2003. Adoption of appropriate statistical methods is
required before the results from such studies can consistently
provide valid information to decision-makers.
Keywords: clinical trials, cost-effectiveness, costs, economic,
randomized controlled trials.
Introduction
With the growing demands on limited health-care
budgets and the need to control the rapid growth in
medical expenditures, the adoption and diffusion of
new medical treatments depends increasingly on evi-
dence of cost and cost-effectiveness. A critical source
of this evidence comes from analyses of economic
information collected prospectively in randomized
clinical trials alongside clinical end points. Yet a sys-
tematic review of all clinical trial-based economic eval-
uations published in 1995 found “major deﬁciencies in
the way cost data in randomized controlled trials were
summarized and analyzed” [1]. In the past decade,
however, the ﬁeld has matured substantially, including
the advancement of, and a growing consensus about,
appropriate statistical methods [2].
In light of these changes, we assessed the methods
used in clinical trial-based economic evaluations pub-
lished in 2003. We speciﬁcally evaluated the methods
used for 1) joint comparison of costs and effects and
assessment of sampling uncertainty; 2) estimation of
incremental costs; and 3) handling of incomplete or
censored cost data.
Methods
Statistical Methods for Cost-Effectiveness Evaluation
Joint comparison of costs and effects and assessment
of sampling uncertainty. A joint comparison of costs
and effects using the incremental cost-effectiveness
ratio (ICER) or the incremental net monetary (health)
beneﬁt (INB) is a useful decision tool to help determine
whether the new therapy offers good value relative to
the alternative. The use of this tool is particularly
important when there is a trade-off between costs and
effects; that is, one therapy is both signiﬁcantly more
effective and more costly compared with the other
therapy. If there is no trade-off between costs and
effects, that is, when one therapy is signiﬁcantly more
effective and less costly when compared with the other
therapy, this decision tool may not be necessary
because that therapy is unambiguously dominant over
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its alternative. A third possibility occurs when the two
treatments have the same effect. In this case, some
authors have interpreted textbooks and guidelines on
health economic evaluations to suggest that a cost-
minimization approach is sufﬁcient (i.e., the lowest-
cost treatment is the treatment of choice) and there is
no need to perform a joint comparison of costs and
effects [3–6]. Nevertheless, as our understanding of
sampling uncertainty for the comparison of costs and
effects has grown, the cases where this interpretation is
appropriate have shrunk.
Because cost-effectiveness ratios and net monetary
beneﬁt estimated from trial data are the result of sam-
ples drawn from the population, one should report the
uncertainty in this outcome that derives from such sam-
pling [7]. Identiﬁcation of methods such as conﬁdence
intervals for cost-effectiveness ratios [8–11], acceptabil-
ity curves [12], and conﬁdence intervals for net mone-
tary beneﬁt [13] for the measurement of this uncertainty
have been important methodologic developments in the
economic evaluation of medical therapies [14]. When
one uses these methods, a ﬁnding of signiﬁcantly lower
cost and an indistinguishable clinical outcome need not
guarantee, one can be conﬁdent that the signiﬁcantly
less expensive therapy is good value. As a result of
uncertainty, the cost-minimization approach has been
shown to be rarely appropriate as a method of analysis
and the need for a joint comparison still remains under
most circumstances [15]. Alternatively, because it is
possible to have more conﬁdence in the combined out-
come of differences in costs and effects than in either
outcome alone, observing no signiﬁcant difference in
costs and effects need not rule out that one can be con-
ﬁdent that one of the two therapies is good value. In
these cases, one should compare costs and effects, and
one should report on their sampling uncertainty.
Estimation of incremental costs. For economic analy-
sis, costs and cost differences between treatment
groups should be expressed by the use of the arithmetic
mean, and not medians, because this summary meas-
ure permits a budgetary assessment of treatment
(N × arithmetic mean = total cost) and is the statistic
of interest for health-care policy decisions [1,2]. The
most common statistical test for arithmetic mean dif-
ferences between treatment groups is the parametric t-
test. Because of the often highly skewed distribution of
cost data, the normality assumption underlying this
test is often called into question and standard nonpar-
ametric tests (e.g., Mann–Whitney U-test or Wilcoxon
rank sum test), or parametric tests on normalizing
transformations (e.g., log transformation) are often
used as a substitute. Yet these popular alternatives are
not appropriate for drawing statistical inferences on
differences in arithmetic mean costs [16–18]. For
example, when one uses a t-test to evaluate the log of
costs, the resulting P-value has direct applicability to
the difference in the log of costs and to the difference
in the geometric mean of costs. It may or may not be
directly applicable to the arithmetic mean costs. Simi-
larly, when one uses a Mann–Whitney U-test, one is
testing differences in the median of costs. Thus, statis-
tical inferences about these other statistics may not be
representative of inferences about the differences in
arithmetic mean, which is the statistic of interest.
If one does not want to adopt a parametric t-test to
directly test for differences in arithmetic mean costs,
one can compare the arithmetic means by using a non-
parametric bootstrap. This procedure has the added
advantage of avoiding a parametric assumption about
the distribution of costs. As a result, the nonparametric
bootstrap has increasingly been recommended either
as a check on the robustness of standard parametric t-
tests, or as the primary statistical test for making infer-
ences about arithmetic means for moderately sized
samples of highly skewed cost data [18–20].
Even if treatment is assigned in a randomized set-
ting, some authors use multivariable techniques to
analyze costs. Multivariable analysis of costs may be
superior to univariate analysis because it improves the
power for tests of differences between groups (by
explaining variation due to other causes). It also facil-
itates subgroup analyses for cost-effectiveness, for
example, more and less severe; different countries/
centers, etc. Finally, it accounts for potentially large
and inﬂuential variations in economic conditions and
practice patterns by provider, center, or country that
may not be balanced by randomization.
Adoption of multivariable analysis does not, how-
ever, avoid the issues that arise in the univariate anal-
ysis of cost. For example, regressions on the
logarithmic transformation of costs were previously
considered an ideal remedy to the violation of the
assumption of normally distributed error term that
underlies ordinary least squares (OLS) regression.
Nevertheless, as the shortcomings of multiple regres-
sion models of log transformed costs became more
widely publicized [17], the use of the generalized linear
models have become the accepted alternative [21–23].
Handling of incomplete cost data. Incomplete or cen-
sored cost data occur in most randomized trials that
follow participants for clinically meaningful lengths of
time. Whether cost data were incomplete, the amount
of incomplete data and the statistical method adopted
to address the problems posed by censoring incomplete
data should routinely be reported in trial-based anal-
yses [2]. Although there exists a mix of approaches to
impute the cost data, recent statistical interest in
addressing censored cost data has led to the proposal of
several methods of estimation that explicitly account
for incomplete data loss-to-follow-up [24–30].
It is well-established that these methods are prone
to less bias than other naive estimation methods
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wherein censored observations are either excluded
from analysis (i.e., complete-case analysis) or included
as though they were complete observations,(i.e., full-
sample analysis) [25,26,28,31–33]. In the ﬁrst naive
approach, only the uncensored cases are used in the
estimation of mean cost and this method is biased
toward the costs of the patients with shorter survival
times because patients with larger survival times are
more likely to be censored [25,32]. Also completely
discarding patients with censored data can lead to the
loss of information and statistical power, which can be
problematic if the percentage of censored cases is high.
The second naive approach which uses all cases with-
out differentiating between censored and uncensored
observations is always biased downward because the
costs incurred after censoring times are not accounted
for [32].
Study Selection
This review included published studies evaluating
economic outcomes based on patient-speciﬁc cost or
resource-use data collected in randomized controlled
trials. A search was conducted in the MEDLINE
database as of September 2004 for all studies which
included terms related to costs (e.g., “cost(s),” “eco-
nomic evaluation(s),” or “health economic(s)”) and
clinical trials (e.g., “trial(s)” or “randomized control-
led trials”) in the title, abstract, or MeSH headings. The
search was limited to publications in English, involving
human subjects, and was published during 2003. This
search identiﬁed approximately 650 eligible articles. A
majority of these studies were excluded upon review of
the study abstract wherein it was clear that they were
not reporting on clinical trial-based economic results.
The full text was reviewed for 162 articles. Studies
were excluded because either the study did not collect
or analyze patient-level costs, or clinical trial data were
applied in a decision-analytic model, or if the study in
fact was not a randomized trial. This resulted in 115
articles being ﬁnally included in the review.
Data Abstraction
Data were extracted by using a specially designed data
abstraction form. The ﬁrst part of the form collected
general study information such as country where trial
was conducted, broad clinical area, and type of inter-
vention. The second part of the form collected speciﬁc
information on the economic outcome studied, the
analysis of costs, and the approach to handling incom-
plete data. We ﬁrst determined whether a joint com-
parison of costs and effects was performed in each
study; and if not, whether it was justiﬁed. For studies
that estimated an ICER or INB, we examined whether
and how stochastic uncertainty was estimated. We
then focused on the analysis of cost data in terms of
how costs were summarized, statistical test used to
compare the costs across treatment groups, and mul-
tivariate technique used to report an adjusted incre-
mental cost estimate. Lastly, we collected information
on whether the study reported incomplete cost data
and technique, if any, used to address the problem.
Assessments were carried out by one assessor
(J.A.D.). The reliability of the data abstraction was
monitored using an independent assessment by a sec-
ond author (H.A.G.) of a 20% random sample of the
115 studies. Agreement was complete for the items
reported in this article. Only in the case of one item
(i.e., technique for handling incomplete cost data) was
discussion needed to determine the classiﬁcation,
because the reporting of methods to account for cen-
sored cost data was unclear in several studies.
Reporting of Results
We report the number and proportion of the 115 stud-
ies that conform and do not conform with each of the
principals for statistical evaluation of cost-effective-
ness set forth above. We also investigate whether the
statistical methods used were associated with the
number of participants in the randomized trial. To do
so, we report selected results stratiﬁed by the sample
size of the study (fewer than 200 subjects, between 200
and 999 subjects, and 1000 or more subjects).
Results
General Study Information
The 115 studies covered a variety of clinical areas
such as cardiovascular disease, musculoskeletal condi-
tions, cancer, and psychiatry. A total of 98 (85%)
studies were published in general medical, surgical, or
subspecialty clinical journals and the remainder were
in methods or policy journals. The trials in which
these economic analyses were performed were con-
ducted in either the United States (27; 24%), the UK
(27; 24%), multinationally (24; 21%), or in other
countries (37; 31%). The economic analysis in 50
(43%) of the 115 studies was based on a sample size
of less than 200 subjects, 47 studies (41%) had
between 200 and 999 subjects, and 18 (16%) had
1000 or more subjects.
Joint Comparison of Costs and Effects and Assessment of 
Sampling Uncertainty
Only 42 (37%) of the 115 identiﬁed studies conducted
a joint comparison of costs and effects (INB [n = 3];
ICER [n = 38]; and cost–beneﬁt ratio [n = 1])
(Table 1). Six studies (5%) divided each therapy’s costs
by its effects, but did not compare incremental costs
with incremental effectiveness. Sixty-seven (58%)
studies reported differences in costs only and did not
jointly compare costs and effects. The lack of a joint
comparison could be justiﬁed in nine of the 73 studies
because one treatment was statistically dominant (sig-
niﬁcantly lower costs and signiﬁcantly better out-
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comes) compared with the alternative. In 38 other
studies, the lack of a joint comparison could possibly
be justiﬁed based on an absence of signiﬁcant differ-
ences in effects between the treatment groups. Hence,
depending on the strictness of the criteria, either 26
(23%) or 64 (56%) of the 115 studies should have esti-
mated costs and effects jointly, but failed to do so.
When we stratiﬁed by sample size, we found that
studies with smaller sample sizes were less likely to
conduct a joint comparison of costs and effects. Again,
depending on the strictness of the criteria, either 14
(28%) or 35 (70%) of the 50 studies with sample sizes
less than 200 failed to conduct a joint comparison. On
the other hand, of the 18 studies with sample sizes of
1000 or more, only two (11%) or four (22%) failed to
estimate costs and effects jointly.
Among the 42 studies that compared costs and
effects, only 24 (57%) reported sampling uncertainty
(Table 1). There was no signiﬁcant difference in this
proportion when we stratiﬁed by sample size (propor-
tions ranged from a low of 54% among studies with
1000 or more participants to a high of 61% among
studies with 200 to 999 participants). When sampling
uncertainty was reported, it was reported appropri-
ately 92% of the time. The methods used in these stud-
ies included acceptability curves (n = 12), 95% CI
obtained from bootstrapping (n = 9), or Fieller’s theo-
rem (n = 1).
Estimation of Incremental Costs
One hundred ten (96%) of the 115 studies reported
arithmetic mean costs by treatment group and 92
(80%) statistically compared costs between treatment
groups (Table 2). Of the 92 statistical comparisons, 62
(68%) used at least one statistical test which was
appropriate for drawing inferences for arithmetic
means (i.e., nonparametric bootstrapping [23%] or
parametric test on untransformed means [45%]). Less
appropriate tests included t-tests on transformed mean
costs (6; 7%) and nonparametric tests of medians or
distributions (17; 18%). In six (7%) of the studies, the
type of test performed was unclear. More than one
type of test were performed in approximately 23% of
these studies: t-tests on untransformed mean costs
were performed 50% of the time, t-tests on trans-
formed mean costs were performed 14% of the time,
and other nonparametric tests were performed 27% of
the time.
Table 1 Joint comparison of costs and effects and sampling
uncertainty
n %
Total number of studies 115 100
Type of cost analysis*
INB 3 3
ICER 38 33
Cost–beneﬁt ratio 1 1
Cost-effectiveness ratio comparison across 
treatment arms
6 5
Mean cost comparison 63 55
Median cost comparison only 4 3
Was joint comparison of costs and effects conducted?
No 73 63
Yes 42 37
If no, was the lack of joint comparison justiﬁed?†
No 26 36
Possibly 38 52
Yes 9 12
If yes, was stochastic uncertainty measured?
No 18 43
Yes 24 57
If yes, how was stochastic uncertainty measured?*
Acceptability curves 12 50
95% CI using bootstrapping 9 38
95% CI using Fieler’s theorem 1 4
Other‡ 2 8
*Mutually exclusive hierarchical classiﬁcation in the order listed.
†“No” refers to studies wherein one treatment arm was signiﬁcantly more effective
but not less costly than the other treatment arm(s), or one treatment arm was more
effective but no statistical comparison of costs reported or no statistical comparison
on either costs or effects reported; “Possibly” refers to studies wherein there was no
signiﬁcant difference in effects across the treatment arms; and “Yes” refers to studies
wherein one treatment arm was signiﬁcantly more effective and less costly (i.e., dom-
inant) than the other treatment arm(s).
‡One study calculated 95% CI for ICER based on 95% CI values for only the numer-
ator (i.e., costs) and another calculated 95% CI but did not specify how these were
estimated.
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; INB, incremental
net beneﬁts.
Table 2 Analysis of costs
n %
Total number of studies 115 100
Type of cost comparison reported across treatment arms
Mean costs only 96 84
Mean and median 14 12
Median costs only 5 4
Was statistical comparison of costs across treatment arms made?
No 23 20
Yes 92 80
If yes, what type of statistical test was conducted?*
Nonparametric bootstrapping 21 23
t-test on untransformed mean costs 41 45
Other parametric test on untransformed mean costs† 1 1
t-test on transformed mean costs‡ 6 7
Mann–Whitney U-test/Wilcoxon rank sum test to infer 
differences in mean costs
9 10
Mann–Whitney U-test/Wilcoxon rank sum test on median 
costs
5 5
Kruskal–Wallis test on distribution of costs 1 1
Kolmogorov–Smirnov test on distribution of costs 2 2
Not clear 6 7
Were adjusted incremental costs reported?
No 105 91
Yes 10 9
If yes, what type of multivariate model was estimated?
OLS 7 70
Log OLS with smearing retransformation 1 10
Generalized linear models 0 0
Other§ 2 20
*Mutually exclusive hierarchical classiﬁcation in the order listed.
†Wald type test proposed by Zhou et al. (1999).
‡Mainly includes logarithmic transformations; only one study conducted a square-
root transformation.
§Includes one study which conducted two-stage probit and tobit regressions and
another which used a linear mixed model.
OLS, ordinary least square.
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Only 10 (9%) of the 115 studies conducted multi-
variate adjustment of the incremental costs. Seven of
these estimated multiple regressions using OLS on
untransformed costs. In addition to producing inefﬁ-
cient estimates in the face of non-normality, OLS has
the disadvantage of not being robust in small- to
medium-sized data sets and in large data sets with
extreme observations. One study estimated OLS mod-
els on log transformed costs and conducted a smearing
retransformation of the estimates to the untransformed
scale. Nevertheless, this study did not provide sufﬁcient
information to judge whether the speciﬁc smearing
retransformation that was adopted was appropriate.
No study estimated generalized linear models. Studies
with sample sizes less than 200 (1; 2%) were less likely
to conduct multivariate adjustment than studies with
sample sizes of 200 or more (9; 14%).
Handling of Incomplete Cost Data
In our sample of economic evaluations, 26 (23%)
reported no attrition, 67 (58%) reported some incom-
plete cost data, and the remaining 22 (19%) did not
indicate whether or not complete follow-up was
achieved (Table 3). In our examination of how the 67
studies with incomplete cost data dealt with the issue,
we found that 19 (28%) studies used various
approaches to impute the missing costs. Two of these
studies used a published statistical approach to
address the issues posed by censored cost data: one
used a regression-based method by Carides et al.
(2000) [30] and the other used the Kaplan–Meier sam-
ple average estimator by Lin et al. (1997) [25]. More
than one-third (26; 39%) of the studies conducted a
complete-case analysis. This method could pose prob-
lems when there are a large number of subjects with
incomplete cost data. We found half of the studies
using complete-case analysis had more than 15% of
observations with censored cost values. Another three
studies (4%) used the naive approach of a full-sample
analysis by ignoring censoring and averaging costs
over all patients. It was not clear how the remaining
19 (28%) studies dealt with incomplete cost data.
Only seven (10%) of the 67 studies conducted a sen-
sitivity analysis using an alternative method of han-
dling incomplete cost data.
Discussion
The number of clinical trial-based economic evalua-
tions has increased considerably over the last decade.
This review identiﬁed 115 such studies published in
2003 compared with the 45 studies published in 1995
that were identiﬁed in a previous review [1]. In the
same time frame, research has also improved the meth-
odologies for analysis and reporting of cost data
collected alongside clinical trials. In light of these
advances, the comparison of our key ﬁndings with
those of the 1995 review suggests that published stud-
ies have begun to use some of these new statistical
techniques. For example, the number of studies per-
forming a statistical test for the cost comparison
increased from 53% to 80%; speciﬁcally, the propor-
tion of these studies performing nonparametric boot-
strapping increased from 0% to 23%. Similarly, the
number of studies reporting INB or ICER increased
over threefold; in addition, more than half of these
studies also reported stochastic uncertainty around
these joint estimates relative to none in 1995.
Nevertheless, in terms of absolute numbers, our
review reveals that there are still a substantial number
of clinical trial-based economic studies using statistical
methods of poor quality. For example, about one in
ﬁve studies did not perform a statistical test for the cost
comparison and yet made claims about cost-effective-
ness or cost-savings. Although the remainder statisti-
cally evaluated costs, about a quarter of these either
performed the inappropriate statistical test for arith-
metic means or only compared median costs. About
one in 10 studies estimated adjusted costs; and a
majority of these used multivariate models that poten-
tially faced issues in terms of bias or efﬁciency of esti-
mation. Only half of the studies calculating an
incremental cost-effectiveness estimate reported some
appropriate measure of stochastic uncertainty. Finally,
although almost two-thirds of the studies reported
some incomplete cost data, only two studies used a
published statistical approach to handle censored cost
data. Both these studies had at least one coauthor who
was also an author on the original statistical methods
paper [25,30].
Table 3 Handling of incomplete cost data
n %
Total number of studies 115 100
Was there incomplete cost data?
No 26 23
Yes 67 58
Not reported 22 19
If yes, what was the primary method used to handle 
incomplete cost data?
Imputation approach 19 28
Lin et al. (1997) method 1 2
Carides et al. (2000) method 1 2
Imputation of group-speciﬁc univariate mean
or median
6 9
Imputation-using regression 3 4
Repeated measures analysis* 3 4
Per person per unit time measure 2 3
Last observation carry forward 3 4
Full-sample analysis 3 4
Complete-case analysis 26 39
Not clear 19 28
If yes, was sensitivity analysis conducted using an 
alternative method of handling incomplete cost?
No 60 90
Yes 7 10
*Use of linear mixed models or generalized estimating equations.
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The International Society for Pharmacoeconomics
and Outcomes Research has recently published a best
practices document for the design, conduct, and report-
ing of economic analyses alongside clinical trials [2].
Whether explicit guidelines alone will foster improve-
ments in the quality of future studies remains a ques-
tion, given previous research that suggests that such
guidelines have had minimal or slow impact in improv-
ing the quality of subsequent studies [6,34–36]. Part of
this problem may be that most of the advances in the
statistical techniques for analyzing cost data have been
published in highly technical economic or biostatistics
journals. Although some applied researchers may not
be reading such literature, many may have difﬁculty
understanding the rationale for and implementation of
these technical methods. There is a clear need for pub-
lications in more applied journals that focus on
explaining these technical advances in an easily under-
standable format to conduct knowledge transfer to
researchers who need to be applying these newer meth-
ods. Additional efforts to improve the quality of future
studies may involve peer reviewers for both funding
agencies and journals being critical of studies that fail
to apply best practices in economic evaluations in clin-
ical trials. Regulatory and reimbursement authorities
should also explicitly adopt best practices guidelines
and uphold all economic data submissions to these
high standards while making reimbursement decisions.
The growing number of economic evaluations being
incorporated in prospective clinical trials reﬂects an
increasing amount of monetary investments, both pri-
vate and public dollars, being made for the additional
collection and analysis of economic end points along-
side clinical trials. Hence, to obtain “value” for our
money, it is necessary to immediately ensure the qual-
ity and consistency of these studies to result in efﬁcient
health-care resource allocation decisions.
Conclusion
Our review ﬁnds that the quality of the methods used
for analysis of costs collected alongside clinical trials
has been improved over the decade; however, there still
remains large room for progress. Meanwhile, decision-
makers need to be cautious while interpreting the
results of current clinical trial-based economic evalua-
tions because some may provide misleading conclu-
sions given the substantial variation in the statistical
methodology and reporting of cost analyses revealed in
this review. Efforts are needed from different stake-
holders to ensure that future clinical trial-based cost-
effectiveness analyses address these issues to enhance
the validity of their ﬁndings and ensure their usefulness
in health-care decision-making.
Source of ﬁnancial support: This study was funded by the
National Institute on Alcohol Abuse and Alcoholism (R01-
AA12664) and the National Institute of Drug Abuse (RO1-
DA017221).
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